Overall, the investigators found the Qorvo Omnia platform design intuitive and easy to use while producing rapid test results compared to high-sensitivity molecular testing systems, with test results within 20 minutes from sample collection. Sensitivity and specificity for the study were 100% below those levels. Three pediatric samples that tested negative on the Qorvo Omnia Antigen Test had Cycle threshold (Ct) values greater than 38 on the Hologic system, indicating very low viral loads in those samples. The studies demonstrated 100% sensitivity/specificity for the adult population, and 83% sensitivity and 100% specificity for the pediatric group. The adult and pediatric studies compared performance of the platform to the Roche cobas 6800 (1800 NDU/ml using FDA reference panel) and Hologic Panther (600 NDU/ml) RT-PCR systems, respectively. Atlanta's Center for Microsystems Engineered Point-of-Care Technologies (ACME-POCT) completed two independent studies, an adult study and a pediatric study, verifying the low SARS-CoV-2 limit of detection (LOD) and high specificity/sensitivity of the Qorvo Omnia Antigen Test. GREENSBORO, NC – J– Qorvo ® (Nasdaq:QRVO), a leading provider of innovative RF solutions that connect the world, a leading provider of innovative radio frequency (RF) solutions that connect the world, announced that the Qorvo Omnia™ SARS-CoV-2 Antigen Test platform completed a key milestone for the NIH Rapid Acceleration of Diagnostics (RADxSM) initiative. Independent study is an important step in verifying the quality of the Qorvo Omnia Antigen Test for use Go to Corporate Social and Environmental Responsibility.People Power and Qorvo Deliver Smart Internet of Things Systems.
#Omnia diagnostics driver
Pre-Switch CleanWave200 DC to AC Power Block.Internet of Things For Dummies® 2nd Edition.A Comprehensive Guide to mmWave Solutions.Ultra-Wideband & CCC® Digital Key E-Guide.AC/DC & High-Voltage DC/DC Power Supplies.Corporate Social and Environmental Responsibility.
0 kommentar(er)
